Modulation of dopamine transmission by 5HT2C and 5HT3 receptors: A role in the antidepressant response

Current Drug Targets

Volumn 7, Issue 2, 2006, Pages 165-175

  Dremencov, Eliyahu ^a,b,c   Weizmann, Yifat ^a   Kinor, Noa ^a   Gispan Herman, Iris ^a   Yadid, Gal ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b JERUSALEM COLLEGE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Animal model of depression; Dopamine; Flinder Sensitive Line rats; Mirtazapine; Nefazodone; Nucleus accumbens; Venlafaxine; Ventral striatum

Indexed keywords

8 [4 (5 AMINO 2,4 DIMETHOXYBENZOYL)BUTYL] 1,3,8 TRIAZASPIRO[4.5]DECANE 2,4 DIONE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; FLUOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANHEDONIA; DEPRESSION; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; ELECTROCONVULSIVE THERAPY; FORCED SWIMMING TEST; HUMAN; MAJOR DEPRESSION; MESOLIMBIC DOPAMINERGIC SYSTEM; MOTIVATION; NONHUMAN; NUCLEUS ACCUMBENS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECT; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DOPAMINE; HUMANS; NUCLEUS ACCUMBENS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN, 5-HT3;

EID: 33644861238     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945006775515491     Document Type: Review

References (96)

1. Nestler, E.J. (1998) Biol. Psychiatry, 44, 526-533.
2. Ressler, K.J. and Nemerof, C.B. (1999) Biol. Psychiatry, 46, 1219-1233.
3. Artigas, F., Celada, P., Laruelle, M. and Adell, A. (2001) Trends Pharmacol. Sci., 22, 224-228.
4. Briner, K. and Dodel, R. C. (1998) Curr. Pharm. Des., 4, 291-302.
5. Blier, P. (2001) J. Clin. Psychiatry, 62(Suppl 15), 12-17.
6. Blier, P. (2003) Eur. Neuropsychopharmacol., 13, 57-66.
7. Ballesteros, J. and Callado, L.F. (2004) J. Affect. Disord., 79, 137-147.
8. Dremencov, E., Gispan-Herman, I., Rosenstein, M., Mendelman, A., Overstreet, D.H., Zohar, J. and Yadid, G. (2004) Prog. Neuropsychopharmacol. Biol. Psychiatry, 28, 141-147.
9. Dremencov, E., Newman, M.E., Kinor, N., Blatman-Jan, G., Schindler, C.J., Overstreet, D.H. and Yadid, G. (2005) Neuropharmacology, 48, 34-42.
10. Zangen, A., Overstreet, D.H. and Yadid, G. (1997) J. Neurochem., 69, 2477-2483.
11. Zangen, A., Overstreet, D.H. and Yadid, G. (1999) Brain Res., 824, 243-250.
12. Zangen, A., Nakash, R., Overstreet, D.H. and Yadid, G. (2001) Psychopharmacology (Berl.), 155, 434-439.
13. Yadid, G., Nakash, R., Deri, I., Tamar, G., Kinor, N., Gispan, I. and Zangen, A. (2000) Prog. Neurobiol., 62, 353-378.
14. Yadid, G., Zangen, A., Dmitrochenko, A., Overstreet, D. and Zobar, J. (2000) Drug Dev. Res., 50, 392-399.
15. Friedman, A., Dremencov, E., Crown, H., Levy, D., Mintz, M., Overstreet, D.H. and Yadid, G. (2005) Neuroreport, 16, 513-516.
16. Overstreet, D.H., Pucilowski, O., Rezvani, A.H. and Janowsky, D.S. (1995) Psychopharmacology (Berl.), 121, 27-37.
17. Overstreet, D.H., Daws, L.C., Schiller, G.D., Orbach, J. and Janowsky, D.S. (1998) Pharmacol. Biochem. Behav., 59, 777-785.
18. Overstreet, D.H. (2002) Behav. Genet., 32, 335-348.
19. Porsolt, R.D. (1979) Biomedicine, 30, 139-140.
20. Porsolt, R.D., Bertin, A. and Jalfre, M. (1977) Arch. Int. Pharmacodyn. Ther., 229, 327-336.
21. Porsolt, R.D., Bertin, A. and Jalfre, M. (1978) Eur. J. Pharmacol., 51, 291-294.
22. Porsolt, R.D., Anton, G., Blavet, N. and Jalfre, M. (1978) Eur. J. Pharmacol., 47, 379-391.
23. Kelliher, P., Kelly, J.P., Leonard, B.E. and Sanchez, C. (2003) Psychoneuroendocrinology, 28, 332-347.
24. Sanchez, C. and Meier, E. (1997) Psychopharmacology (Berl), 129, 197-205.
25. Connor, T.J., Kelliher, P., Harkin, A., Kelly, J.P. and Leonard, B.E. (1999) Eur. J. Pharmacol., 379, 125-133.
26. Wong, E.H., Sonders, M.S., Amara, S.G., Tinholt, P.M., Piercey, M.F., Hoffmann, W.P., Hyslop, D.K., Franklin, S., Porsolt, R.D., Bonsignori, A., Carfagna, N. and McArthur, R.A. (2000) Biol. Psychiatry, 47, 818-829.
27. Connor, T.J., Kelliher, P., Shen, Y., Harkin, A., Kelly, J.P. and Leonard, B.E. (2000) Pharmacol. Biochem. Behav., 65, 591-597.
28. West, C.H. and Weiss, J.M. (1998) Pharmacol. Biochem. Behav., 61, 67-79.
29. Rogoz, Z., Skuza, G., Maj, J. and Danysz, W. (2002) Neuropharmacology, 42, 1024-1030.
30. Thompson, C. (1999) J. Clin. Psychiatry, 60 (Suppl 17), 18-22.
31. Bech, P. (2001) Int. J. Neuropsychopharmacol., 4, 337-345.
32. Versiani, M., Moreno, R., Ramakers-van Moorsel, C.J. and Schutte, A.J. (2005) CNS Drugs, 19, 137-146.
33. Wade, A., Crawford, G.M., Angus, M., Wilson, R. and Hamilton, L. (2003) Int. Clin. Psychopharmacol., 18, 133-141.
34. Thase, M.E., Entsuah, A.R. and Rudolph, R.L. (2001) Br. J. Psychiatry, 178, 234-241.
35. Stahl, S.M., Entsuah, R. and Rudolph, R.L. (2002) Biol. Psychiatry, 52, 1166-1174.
36. Mongeau, R., Blier, P. and de Montigny, C. (1997) Brain Res. Rev., 23, 145-195.
37. Dremencov, E., Gur, E., Lerer, B. and Newman, M.E. (2003) Prog. Neuropsychopharmacol. Biol. Psychiatry, 27, 729-739.
38. Sullivan, R.M. and Gratton, A. (2002) Psychoneuroendocrinology, 27, 99-114.
39. Dremencov, E., Gur, E., Lerer, B. and Newman, M.E. (2002) Prog. Neuropsychopharmacol. Biol. Psychiatry, 26, 1029-1034.
40. Jay, T.M., Rocher, C., Hotte, M., Naudon, L., Gurden, H. and Spedding, M. (2004) Neurotox. Res., 6, 233-244.
41. Rogers, M.A., Kasai, K., Koji, M., Fukuda, R., Iwanami, A., Nakagome, K., Fukuda, M. and Kato, N. (2004) Neurosci. Res., 50, 1-11.
42. Drevets, W.C. (2003) Ann. N Y. Acad. Sci., 985, 420-444.
43. Phillips, A.G., Ahn, S. and Howland, J.G. (2003) Neurosci. Biobehav. Rev., 27, 543-554.
44. Parent, A., Hazrati, L.N. and Charara, A. (1997) Adv. Neurol., 74, 19-29.
45. Alexander, G.E., DeLong, M.R. and Strick, P.L. (1986) Annu. Rev. Neurosci, 9, 357-381.
46. Bergman, H., Feingold, A., Nini, A., Raz, A., Slovin, H., Abeles, M., Vaadia, E. (1998) Trends Neurosci., 21(Suppl 1), 32-38
47. Ikemoto, S. and Panksepp, J. (1999) Brain Res. Rev., 31, 6-41.
48. Kapur, S. and Mann, J.J. (1992) Biol. Psychiatry, 32, 1-17.
49. McLean, A., Rubinsztein, J.S., Robbins, T.W. and Sahakian, B.J. (2004) Psychopharmacology (Berl), 171, 286-297.
50. Pania, L. and Gessab, G.L. (2002) Int. Clin. Psychopharmacol., 17 Suppl 4, S1-S7.
51. Bymaster, F.P., McNamara, R.K. and Tran, P.V. (2003) Expert. Opin. Investig. Drugs, 12, 531-543.
52. Pacak, K., Tjurmina, O., Palkovits, M., Goldstein, D.S., Koch, C.A., Hoff, T. and Chrousos, G.P. (2002) Neuroendocrinology, 76, 148-157.
53. Kram, M.L., Kramer, G.L., Ronan, P.J., Steciuk, M. and Petty, F. (2002) Prog. Neuropsychopharmacol. Biol. Psychiatry, 26, 639-645.
54. Meyer, J.H., Kruger, S., Wilson, A.A., Christensen, B.K. Goulding, V.S., Schaffer, A., Minifie, C., Houle, S., Hussey, D. and Kennedy, S.H. (2001) Neuroreport, 12, 4121-4125.
55. Korf, J. and Van Praag, H.M. (1971) Brain Res., 35, 221-230.
56. Traskman, L., Asberg, M., Bertilsson, L. and Sjostrand, L. (1981) Arch. Gen. Psychiatry, 38, 631-636.
57. Meyer, J.H., Goulding, V.S., Wilson, A.A., Hussey, D., Christensen, B.K. and Houle, S. (2002) Psychopharmacology (Berl), 163, 102-105.
58. Laruelle, M., D'Souza, C.D., Baldwin, R.M., Abi-Dargham, A., Kanes, S.J., Fingado, C.L., Seibyl, J.P., Zoghbi, S.S., Bowers, M.B., Jatlow, P., Charney, D.S. and Innis, R.B. (1997) Neuropsychopharmacology, 17, 162-174.
59. Ginovart, N., Farde, L., Halldin, C. and Swahn, C.G. (1997) Synapse, 25, 321-325.
60. Tanda, G., Carboni, E., Frau, R. and Di Chiara, G. (1994) Psychopharmacology (Berl), 115, 285-288.
61. Olausson, P., Ericson, M., Petersson, A., Kosowski, A., Soderpalm, B. and Engel, J.A. (1998) Alcohol, 15, 77-86.
62. Nakayama, K., Sakurai, T. and Katsu, H. (2004) Brain Res. Bull., 63, 237-241.
63. Weikop, P., Kehr, J. and Scheel-Kruger, J. (2004) J. Psychopharmacol., 18, 395-403.
64. Bymaster, F.P., Zhang, W., Carter, P.A., Shaw, J., Chernet, E., Phebus, L., Wong, D.T. and Perry, K.W. (2002) Psychopharmacology (Berl), 160, 353-361.
65. Koch, S., Perry, K.W., Nelson, D.L., Conway, R.G., Threlkeld, P.G. and Bymaster, F.P. (2002) Neuropsychopharmacology, 27, 949-959.
66. Nakayama, K. (2002) Naunyn. Schmiedebergs Arch. Pharmacol., 365, 102-105.
67. Parsons, L.H. and Justice, J.B., Jr. (1993) Brain Res., 606, 195-199.
68. Ichikawa, J. and Meltzer, H.Y. (1999) J. Pharmacol. Exp. Ther., 291, 1227-1232.
69. Lucas, G. and Spampinato, U. (2000) J. Neurochem., 74, 693-701.
70. Campbell, A.D. and McBride, W.J. (1995) Pharmacol. Biochem. Behav., 51, 835-842.
71. Di Matteo, V., De Blasi, A., Di Giulio, C. and Esposito, E. (2001) Trends Pharmacol. Sci., 22, 229-232.
72. Di Giovanni, G., Di Matteo, V. and Esposito, E. (2002) Indian J. Exp. Biol., 40, 1344-1352.
73. Cameron, D.L. and Williams, J.T. (1995) Clin. Exp. Pharmacol. Physiol., 22, 841-845.
74. Gothert, M. (1990) Ann. N Y. Acad Sci., 604, 102-112.
75. Gobert, A., Rivet, J. M., Lejeune, F., Newman-Tancredi, A., Adhumeua-Auclair, A., Nicholas, J. P., Cistarelli, L., Melon, C., and Millan, M. J. (2002) Synapse, 36, 205-221.
76. de Boer, T. (1995) Int. Clin. Psychopharmacol., 10(Suppl 4), 19-23.
77. de Boer, T. (1996) J. Clin. Psychiatry, 57(Suppl 4), 19-25.
78. Ellingrod, V.L. and Perry, P.J. (1995) Am. J. Health Syst. Pharm., 52, 2799-2812.
79. Sanchez, C. and Hyttel, J. (1999) Cell Mol. Neurobiol., 19, 467-489.
80. Yao, M. and Srinivas, N.R. (2000) Biomed. Chromatogr., 14, 106-112.
81. Blier, P. and Bouchard, C. (1993) Br. J. Pharmacol., 108, 13-22.
82. Kennett, G.A., Lightowler, S., de Biasi, V., Stevens, N.C., Wood, M.D., Tulloch, I.F. and Blackburn, T.P. (1994) Neuropharmacology, 33, 1581-1588.
83. Cremers, T.I., Giorgetti, M., Bosker, F.J., Hogg, S., Arnt, J., Mork, A., Honig, G., Bogeso, K.P., Westerink, B.H., den Boer, H., Wikstrom, H.V. and Tecott, L.H. (2004) Neuropsychopharmacology, 29, 1782-1789.
84. Yamada, J. and Sugimoto, Y. (2001) Eur. J. Pharmacol., 427(3), 221-225.
85. Rosel, P., Arranz, B., San, L., Vallejo, J., Crespo, J.M., Urretavizcaya, M. and Navarro, M.A. (2000) Psychiatry Res., 99, 173-181.
86. Loo, H., Hale, A. and D'haenen, H. (2002) Int. Clin. Psychopharmacol., 17, 239-247.
87. Giorgetti, M. and Tecott, L.H. (2004) Eur. J. Pharmacol., 488, 1-9.
88. Wang, Q., Khillan, J., Gadue, P. and Nishikura, K. (2000) Science, 290, 1765-1768.
89. Wang, Q., O'Brien, P.J., Chen, C.X., Cho, D.S., Murray, J.M. and Nishikura, K. (2000) J. Neurochem., 74, 1290-1300.
90. Herrick-Davis, K., Grinde, E. and Niswender, C.M. (1999) J. Neurochem., 73, 1711-1717.
91. Gurevich, I., Tamir, H., Arango, V., Dwork, A.J., Mann, J.J. and Schmauss, C. (2002) Neuron, 34, 349-356.
92. Lubbert, H., Snutch, T.P., Dascal, N., Lester, H.A. and Davidson, N. (1987) J. Neurosci., 7, 1159-1165.
93. Julius, D. (1998) Proc. Natl. Acad. Sci. USA, 95, 15153-15154.
94. Brady, C.A., Stanford, I.M., Ali, I., Lin, L., Williams, J.M., Dubin, A.E., Hope, A.G. and Barnes, N.M. (2001) Neuropharmacology, 41, 282-284.
95. Artigas, F., Nutt, D.J. and Shelton, R. (2002) Psychopharmacol. Bull., 36(Suppl 2), 123-132.
96. Bakish, D., Hooper, C.L., Thornton, M.D., Wiens, A., Miller, C.A. and Thibaudeau, C.A. (1997) Int. Clin. Psychopharmacol., 12, 91-97.